EQS-Adhoc

Cassiopea announces results of AGM 2021 - Seite 2

- Confirmation of BDO Italia SpA's mandate for the statutory audit of the accounts of the Company for the financial years 2021-2023.

About Cassiopea

Cassiopea is a specialty pharmaceutical company developing and preparing to commercialize prescription drugs with novel mechanisms of action (MOA) to address long-standing and essential dermatological conditions, particularly acne, androgenetic alopecia (or AGA) and genital warts. Cassiopea is investing in innovation that is driving scientific advancement in areas that have been largely ignored for decades. The portfolio comprises four unencumbered clinical candidates, for which Cassiopea owns the worldwide rights. The Company's strategy is to leverage this expertise to optimize the commercial potential for its products directly or with a partner. For further information on Cassiopea, please visit www.cassiopea.com.

Next events

Jefferies Virtual Global Health Care Conference Half-Year Report 2021 Credit Suisse Equity Conference Jefferies Global Health Care Conference

June 1-3, 2021 July 29 2021 Mid-November 2021, Zurich November 16-18, 2021, London

Contact

Cassiopea SpA
Diana Harbort, CEO & Head of Investor Relations
Tel: [phone]
[e-mail]

Some of the information contained in this press release may contain forward-looking statements. Readers are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those in the forward-looking statements as a result of various factors. Cassiopea has no obligation to publicly update or revise any forward-looking statements.